Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 156

1.

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report.

Flora A, Pipoly D.

Drug Saf Case Rep. 2018 Jan 17;5(1):5. doi: 10.1007/s40800-017-0070-z.

2.

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations.

Nichols AI, Liao S, Abbas R.

Clin Pharmacol Drug Dev. 2017 Dec 11. doi: 10.1002/cpdd.419. [Epub ahead of print]

PMID:
29228473
3.

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB.

J Child Adolesc Psychopharmacol. 2017 Nov 30. doi: 10.1089/cap.2017.0100. [Epub ahead of print]

PMID:
29189044
4.

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.

Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL.

J Child Adolesc Psychopharmacol. 2017 Nov 29. doi: 10.1089/cap.2017.0099. [Epub ahead of print]

PMID:
29185786
5.

Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review.

Lee Y, Rosenblat JD, Lee J, Carmona NE, Subramaniapillai M, Shekotikhina M, Mansur RB, Brietzke E, Lee JH, Ho RC, Yim SJ, McIntyre RS.

J Affect Disord. 2017 Nov 7;227:406-415. doi: 10.1016/j.jad.2017.11.003. [Epub ahead of print] Review.

PMID:
29154157
6.

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.

Soares CN, Zhang M, Boucher M.

CNS Spectr. 2017 Nov 15:1-11. doi: 10.1017/S1092852917000633. [Epub ahead of print]

PMID:
29140227
7.

Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors.

Sinha P, Shetty DJ, Bairy LK, Andrade C.

Asian J Psychiatr. 2017 Oct;29:148-153. doi: 10.1016/j.ajp.2017.06.003. Epub 2017 Jun 2.

PMID:
29061415
8.

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M.

J Clin Psychopharmacol. 2017 Oct;37(5):555-561. doi: 10.1097/JCP.0000000000000775.

9.

The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.

Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, Lam RW.

Int Clin Psychopharmacol. 2017 Nov;32(6):343-349. doi: 10.1097/YIC.0000000000000192.

PMID:
28763344
10.

Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.

Lam RW, Wajsbrot DB, Meier E, Pappadopulos E, Mackell JA, Boucher M.

J Psychopharmacol. 2017 Sep;31(9):1204-1214. doi: 10.1177/0269881117719261. Epub 2017 Jul 18.

PMID:
28718346
11.

Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.

Alcocer-Gómez E, Casas-Barquero N, Williams MR, Romero-Guillena SL, Cañadas-Lozano D, Bullón P, Sánchez-Alcazar JA, Navarro-Pando JM, Cordero MD.

Pharmacol Res. 2017 Jul;121:114-121. doi: 10.1016/j.phrs.2017.04.028. Epub 2017 May 2.

PMID:
28465217
12.

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

Mosca D, Zhang M, Prieto R, Boucher M.

J Clin Psychopharmacol. 2017 Apr;37(2):182-192. doi: 10.1097/JCP.0000000000000674.

PMID:
28146000
13.

Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.

Hellerstein DJ, Hunnicutt-Ferguson K, Stewart JW, McGrath PJ, Keller S, Peterson BS, Chen Y.

J Affect Disord. 2017 Mar 1;210:258-264. doi: 10.1016/j.jad.2016.12.026. Epub 2016 Dec 20.

PMID:
28064115
14.

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.

Solem CT, Shelbaya A, Wan Y, Deshpande CG, Alvir J, Pappadopulos E.

Neuropsychiatr Dis Treat. 2016 Oct 25;12:2755-2764. eCollection 2016.

15.

Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial.

Manber R, Buysse DJ, Edinger J, Krystal A, Luther JF, Wisniewski SR, Trockel M, Kraemer HC, Thase ME.

J Clin Psychiatry. 2016 Oct;77(10):e1316-e1323. doi: 10.4088/JCP.15m10244.

PMID:
27788313
16.

Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study.

Edinger JD, Manber R, Buysse DJ, Krystal AD, Thase ME, Gehrman P, Fairholme CP, Luther J, Wisniewski S.

J Clin Sleep Med. 2017 Feb 15;13(2):205-213. doi: 10.5664/jcsm.6448.

17.
18.

Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing.

Misri S, Swift E, Abizadeh J, Shankar R.

Ther Adv Psychopharmacol. 2016 Aug;6(4):269-76. doi: 10.1177/2045125316656297. Epub 2016 Jun 24.

19.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):909-921. Epub 2016 Jul 18.

PMID:
27428303
20.

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.

Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, Chaimani A, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Suganuma A, Watanabe N, Stockton S, Geddes JR, Cipriani A.

BMJ Open. 2016 Jul 8;6(7):e010919. doi: 10.1136/bmjopen-2015-010919.

Supplemental Content

Loading ...
Support Center